Susan Butler-sumner, MD | |
28 Rome Rd, Cave Spring, GA 30124-0000 | |
(706) 777-8775 | |
Not Available |
Full Name | Susan Butler-sumner |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 42 Years |
Location | 28 Rome Rd, Cave Spring, Georgia |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205896305 | NPI | - | NPPES |
008704420 | Medicaid | AL | |
00344825A | Medicaid | GA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 01201822021 (Georgia) | Secondary |
207Q00000X | Family Medicine | 29851 (Georgia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Redmond Regional Medical Center | Rome, GA | Hospital |
Mailing Address | Practice Location Address |
---|---|
Susan Butler-sumner, MD 28 Rome Rd, Cave Spring, GA 30124-0000 Ph: (706) 777-8775 | Susan Butler-sumner, MD 28 Rome Rd, Cave Spring, GA 30124-0000 Ph: (706) 777-8775 |
News Archive
Cell biologist Carolyn Machamer, Ph.D is The Pew Charitable Trusts' biomedical researcher of the month for her creative work on coronaviruses. Specifically, Machamer studies how the family of viruses uses a host cell's machinery against it.
Norwegian researchers have developed a hip protector in a sporty design. Its looks are intended to appeal to the older people of today - who are quite particular about what they will wear.
The debate over Darwin rages on in America's heartland as intelligent design comes to the Sam Noble Oklahoma Museum of Natural History September 29th with the Southwestern debut of Darwin's Dilemma, a new film on the challenges to evolution in the fossil record. To view a trailer and clips from the film please visit www.darwinsdilemma.org.
A $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations.
Palatin Technologies, Inc. announced today that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications.
› Verified 8 days ago